Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCARH125 + MCARH109
- Development stage
- Phase 1
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
MCARH125 + MCARH109 is an investigational combination regimen consisting of two autologous chimeric antigen receptor (CAR) T-cell therapies: MCARH125, which targets B-cell maturation antigen (BCMA), and MCARH109, which targets G-protein coupled receptor class C group 5 member D (GPRC5D). Developed by Memorial Sloan Kettering Cancer Center (MSK) in collaboration with Eureka Therapeutics and Juno Therapeutics (a subsidiary of Bristol Myers Squibb), this dual-targeting cell therapy is designed to treat relapsed or refractory multiple myeloma. By simultaneously targeting BCMA and GPRC5D, the combination aims to overcome tumor heterogeneity and prevent single-antigen escape, which are common mechanisms of resistance in myeloma. The therapies are manufactured from a single apheresis and administered sequentially following lymphodepleting conditioning chemotherapy.
- Other names
- MCARH109 + MCARH125MCARH109 and MCARH125MCARH-109 and MCARH125MCARH 109 and MCARH125MCARH125 and MCARH109MCARH-125 and MCARH109MCARH 125 and MCARH109
02
Targets
TNFRSF9 (CD137 extracellular domain)GPRC5DBCMA (Tumor necrosis factor receptor superfamily member 17)
Beyond the preview
Go deeper on MCARH125 + MCARH109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCARH125 + MCARH109.